Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Susan Ling, Felicia Ceban, Leanna M.W. Lui, et al.
CNS Drugs (2021) Vol. 36, Iss. 1, pp. 17-30
Closed Access | Times Cited: 80

Showing 26-50 of 80 citing articles:

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Daniel A Kinderlehrer
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 141-155
Open Access
Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l’étude
Noah Chisamore, Erica Kaczmarek, Zoe Doyle, et al.
The Canadian Journal of Psychiatry (2025)
Closed Access
Targeting HINT1 to improve synaptic plasticity: toward loganin as a new antidepressant strategy
Cong‐Yuan Xia, Guo-Yan Zuo, Manni Wang, et al.
Molecular Psychiatry (2025)
Closed Access
The Use, Role, and Function of Music During Psychedelic-Assisted Therapy (PAT) with Ayahuasca: A Scoping Review Protocol
Guillermo Saúl Escobar Cornejo, Fernando P. Cárdenas, Diego José Lira Torres, et al.
Psychoactives (2025) Vol. 4, Iss. 2, pp. 9-9
Open Access
The evolution and ecology of psilocybin in nature
Matthew J. Meyer, Jason C. Slot
Fungal Genetics and Biology (2023) Vol. 167, pp. 103812-103812
Closed Access | Times Cited: 10
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Roger S. McIntyre
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 10, pp. 881-883
Open Access | Times Cited: 10
Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review
Tessa Watford, Naqash Masood
Clinical Psychopharmacology and Neuroscience (2023) Vol. 22, Iss. 1, pp. 2-12
Open Access | Times Cited: 10
Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Terence H. W. Ching, Lucia Amoroso, Calvin Bohner, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 3
Pediatric suicide: Review of a preventable tragedy
Donald E. Greydanus, Ahsan Nazeer, Zheala Qayyum, et al.
Disease-a-Month (2024) Vol. 70, Iss. 9, pp. 101725-101725
Closed Access | Times Cited: 3
Neurobiology of the Antidepressant Effects of Serotonergic Psychedelics: A Narrative Review
Noah Chisamore, Erica Kaczmarek, Gia Han Le, et al.
Current Treatment Options in Psychiatry (2024) Vol. 11, Iss. 2, pp. 90-105
Closed Access | Times Cited: 3
Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
G. Salvetti, Daniele Saccenti, Andrea Stefano Moro, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 829-829
Open Access | Times Cited: 3
Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system
Shigeyuki Chaki, Mai Watanabe
Neuropharmacology (2022) Vol. 223, pp. 109348-109348
Closed Access | Times Cited: 16
Associations between MDMA/ecstasy, classic psychedelics, and suicidal thoughts and behaviors in a sample of U.S. adolescents
Grant Jones, Diego Arias, Matthew K. Nock
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Psychedelics for treatment resistant depression: are they game changers?
Michail Kalfas, Rosie H. Taylor, Dimosthenis Tsapekos, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 18, pp. 2117-2132
Open Access | Times Cited: 8
Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: A systematic review
James J Gattuso, Carey Wilson, Anthony J. Hannan, et al.
Journal of Neurochemistry (2023)
Open Access | Times Cited: 8
Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats
Jonathan Reinwald, Christian N. Schmitz, Ivan Skorodumov, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Potential Therapeutic Effects of Psilocybin: A Systematic Review
Dev B Goel, Sarju Zilate
Cureus (2022)
Open Access | Times Cited: 13
The Health and Clinical Benefits of Medicinal Fungi
Christopher Hobbs
Advances in biochemical engineering, biotechnology (2023), pp. 285-356
Closed Access | Times Cited: 7
Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test
Arya Rahbarnia, Zhaoxia Li, Paul Fletcher
Psychopharmacology (2023)
Closed Access | Times Cited: 7
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants
Nicole Ledwos, Joshua D. Rosenblat, Daniel M. Blumberger, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 6, pp. 581-588
Closed Access | Times Cited: 12
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Mauro Scala, Chiara Fabbri, Paolo Fusar‐Poli, et al.
CNS Spectrums (2024), pp. 1-15
Closed Access | Times Cited: 2
The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
Hartej Gill, Parnian Puramat, Pankti Patel, et al.
Psychiatry Research (2022) Vol. 313, pp. 114577-114577
Closed Access | Times Cited: 10
Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?
Antonio Munafò, Davide Arillotta, Guido Mannaioni, et al.
Pharmaceuticals (2022) Vol. 16, Iss. 1, pp. 68-68
Open Access | Times Cited: 10
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
Daniel A Kinderlehrer
International Medical Case Reports Journal (2023) Vol. Volume 16, pp. 109-115
Open Access | Times Cited: 6
Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters
Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-abadi, et al.
Fitoterapia (2023) Vol. 169, pp. 105620-105620
Closed Access | Times Cited: 6

Scroll to top